<DOC>
	<DOC>NCT00354094</DOC>
	<brief_summary>The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of [S,S]-Reboxetine in patients with pain after shingles.</brief_summary>
	<brief_title>[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.</brief_title>
	<detailed_description />
	<mesh_term>Reboxetine</mesh_term>
	<criteria>Patients must have pain present for more than 3 months after healing of the shingles skin rash. Patients at screening must have a score of &gt;/=40mm on the pain visual analogue scale. Patients with significant hepatic impairment. Patients with other severe pain, that may impair the selfassessment of pain due to postherpetic neuralgia (pain after shingles).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>